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Abstract
Background: Genetically engineered mouse models are essential to the investigation of the molecular mechanisms
underlying human prostate pathology and the effects of therapy on the diseased prostate. Serial in vivo volumetric
imaging expands the scope and accuracy of experimental investigations of models of normal prostate physiology,
benign prostatic hyperplasia and prostate cancer, which are otherwise limited by the anatomy of the mouse
prostate. Moreover, accurate imaging of hyperplastic and tumorigenic prostates is now recognized as essential to
rigorous pre-clinical trials of new therapies. Bioluminescent imaging has been widely used to determine prostate
tumor size, but is semi-quantitative at best. Magnetic resonance imaging can determine prostate volume very
accurately, but is expensive and has low throughput. We therefore sought to develop and implement a high
throughput, low cost, and accurate serial imaging protocol for the mouse prostate.
Methods: We developed a high frequency ultrasound imaging technique employing 3D reconstruction that allows
rapid and precise assessment of mouse prostate volume. Wild-type mouse prostates were examined (n = 4) for
reproducible baseline imaging, and treatment effects on volume were compared, and blinded data analyzed for
intra- and inter-operator assessments of reproducibility by correlation and for Bland-Altman analysis. Examples of
benign prostatic hyperplasia mouse model prostate (n = 2) and mouse prostate implantation of orthotopic human
prostate cancer tumor and its growth (n = 6) are also demonstrated.
Results: Serial measurement volume of the mouse prostate revealed that high frequency ultrasound was very precise.
Following endocrine manipulation, regression and regrowth of the prostate could be monitored with very low intra-
and interobserver variability. This technique was also valuable to monitor the development of prostate growth in a
model of benign prostatic hyperplasia. Additionally, we demonstrate accurate ultrasound image-guided implantation
of orthotopic tumor xenografts and monitoring of subsequent tumor growth from ~10 to ~750 mm3 volume.
Discussion: High frequency ultrasound imaging allows precise determination of normal, neoplastic and hyperplastic
mouse prostate. Low cost and small image size allows incorporation of this imaging modality inside clean animal
facilities, and thereby imaging of immunocompromised models. 3D reconstruction for volume determination is easily
mastered, and both small and large relative changes in volume are accurately visualized. Ultrasound imaging does not
rely on penetration of exogenous imaging agents, and so may therefore better measure poorly vascularized or necrotic
diseased tissue, relative to bioluminescent imaging (IVIS).
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Conclusions: Our method is precise and reproducible with very low inter- and intra-observer variability. Because it is
non-invasive, mouse models of prostatic disease states can be imaged serially, reducing inter-animal variability, and
enhancing the power to detect small volume changes following therapeutic intervention.
Keywords: Prostate cancer, BPH, Mouse model, IVIS, 3D volume
Background
Prostate cancer (PrCa) is the most prevalent non-cutaneous
cancer and second leading cause of cancer mortality in men
[1]. Despite effective therapy for localized disease, treatment
of recurrent and metastatic PrCa is problematic and there-
fore the focus of intense investigation. Mouse models have
proven valuable for studying human disease, including pros-
tate cancer, because of their short breeding cycles and man-
ageable costs, but particularly because of the ease of genetic
manipulation compared to larger animals. Mice are also use-
ful as immunocompromised hosts for xenografts of human
prostate cancers [2, 3]. Genetically engineered mouse models
have been particularly informative in revealing the molecular
and cellular mechanisms underlying prostate tumor biology,
and to evaluate new therapeutic inventions [4]. Although
fewer models are available, benign prostatic hyperplasia can
also be genetically engineered in mice, which may be useful
in developing therapies for this highly prevalent disease [5].
US Food and Drug Administration approval rates for
drugs has been declining since 1990 and oncology drug
development has been particularly inefficient [6]. Only
about one in twenty drugs entering phase I human clin-
ical trials for cancer are eventually approved and among
those that progress to phase III trials, only about 30 %
are eventually approved [6]. A major cause of this failure
is lack of efficacy in human trials, rather than safety is-
sues. Specifically, the apparent efficacy in murine models
is frequently not replicable in human trials [7, 8]. To en-
hance reproducibility, and ultimately the translation of pre-
clinical trial success into human clinical trials, it has been
proposed that all pre-clinical trials include randomization
of tumor bearing animals to treatment groups; blinding to
those treating, and subsequently evaluating, endpoints; a
pre-determined statistical analysis protocol; and treatment
designs that are adequately powered to test the null hypoth-
eses [9, 10]. Accurate volumetric imaging serves an import-
ant role in executing such rigorous preclinical trials by
ensuring that all animals undergoing randomization to
treatment groups have tumors of similar size. This is par-
ticularly important in models where tumor formation does
not occur in 100 % of mice or where there is significant
variation in the rate of tumor formation [11]. In addition,
live animal imaging of tumor volume provides an accurate
assessment of tumor response kinetics, controlled for
animal-to-animal variation, since each animal serves as its
own control [12]. The alternatives – serially sacrificing
groups of animals at intermediate time points, or simply
measuring tumor size at the end of the trial – are less in-
formative or require many more animals, compromising
the statistical power of the preclinical study design [13].
While rodent and human prostates are functionally equiva-
lent, the mouse prostate is small (~25 mm3), multi-lobular
(ventral, dorsal, lateral and anterior), and interdigitated with
surrounding genitourinary organs. Many reports have moni-
tored prostate tumor growth and regression using optical im-
aging (fluorescence or luciferase reporters). However, tumors
must be engineered to express a reporter gene and quantitation
is very problematic [14, 15], particularly for longitudinal im-
aging [16, 17]. Optical imaging is both higher throughput and
lower in cost than other modalities, but has relatively poor
anatomic resolution [18]. We have previously described a
quantitative and reproducible anatomical imaging approach,
utilizing high-field magnetic resonance imaging with chemical
shift suppression (MRI-CHESS) [19, 20] to measure murine
prostate volumes changes resulting from a variety ofmanipula-
tions in mouse models. Since MRI instrumentation is costly
and not widely available, we sought to develop a 3D-ultrasound
imaging protocol to precisely measure very small changes in
the volume of themouse prostate, in living animals.
High-frequency ultrasound imaging of the mouse pros-
tate has many advantages: it is low cost and high through-
put, enables 3D reconstruction for precise volume
determination, and allows real-time imaging to facilitate
surgical manipulations [21]. Here, we describe the use of
high-resolution in vivo ultrasound imaging for quantitative
analysis of prostate volume. Monitoring changes in the
prostate of normal mice, we demonstrate that this ultra-
sound technique can precisely detect sub-cubic millimeter
changes in volume following hormonal manipulations that
result in regression and regrowth of the normal prostate.
We then apply this technique to two distinct prostate dis-
ease models: growth of the prostate in a prolactin-driven
benign prostatic hyperplasia model [22], and growth of hu-
man prostate cancer orthotopic xenografts implanted in the
anterior lobe of the mouse prostate [23].
Methods
Animals
All animal studies were approved by the University of
Rochester institutional animal use committee (UCAR
#2012-030) and conducted according to the guidelines
of the local committee on animal resources, as well as
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all relevant national guidelines. Six to nine month old
male C57/BL6 mice, and 12–14 week old male nude
mice, used as orthotopic xenograft hosts, were pur-
chased from Charles River Labs. Probasin-driven prolac-
tin (Pb-PRL) transgenic mice were provided by John
Kindbloom [22] and backcrossed into an FVB back-
ground [24]. All mice were housed individually and pro-
vided food and water ad libitum. Endocrine perturbation
was as described previously [19]. Briefly, animals were
anesthetized via intra-peritoneal Ketamine (87 mg/kg)
and Xylazine (13 mg/kg) injection and then surgically
castrated via scrotal incision. Testes were removed, and
blood vessels and vas deferens ligated. The incision was
closed with wound clips. Three days following castra-
tion clips were removed to allow ultrasound imaging.
Fourteen days following castration, 5 mg/kg 5alpha-
androstan-17beta-ol-3-one (dihydrotestosterone, DHT,
Sigma) in corn oil was injected sub-cutaneously daily.
High-resolution ultrasound image acquisition and analysis
Each mouse was imaged with a high-resolution ultrasound
system (Vevo770 high resolution imaging system, VisualSo-
nics, Toronto, Ontario, Canada) using the highest resolution
scan head (either 710 or 704b) that was able to image the
entire prostate or tumor. The 704b scan head probe is
driven by a linear motor with a center frequency of 40 MHz
and provides a 40 μm axial and 80 μm lateral resolution at a
focal depth of 6 mm, affording a 14.5 μm field of view. The
corresponding values for the 710 scan head are 25 MHz,
70 μm×140 μm, and 20.8 μm, respectively. Mice were anes-
thetized in a chamber using 3 % isoflurane and then fixed in
the transverse position on a heated imaging platform (Vevo
Integrated Rail System III, VisualSonics) with a nose cone
for maintenance of anesthesia using 2 % isoflurane. Animals
were monitored for heart rate and respiratory cycle using
surface electrodes. The abdomens of the mice were depilated
using a commercial calcium thioglycolate product (“Nair”),
and ultrasound gel (Aquasonic 100, Parker Laboratories,
Fairfield, NJ) was applied to the abdomen. The location of
the anterior, dorsal and ventral prostate lobes was identified
by mechanically adjusting the position of the ultrasound
transducer, with the bladder and urethra as landmarks. Im-
ages of 585 sections of each ultrasound series were acquired
at a resolution of 1600 × 1200 pixels using the VisualSonics
software. Following acquisition, images were imported into
Amira software (Visualization Sciences Group, Burlington
MA), for 3D mouse prostate volume reconstruction. The
images were set to 8-bit gray scale and the contrast en-
hanced using Amira. Anatomic boundaries of the prostate
lobes were manually outlined in parallel slices. Based on
these areas, the volume was subsequently computed with
Amira. Slice alignment, segmentation and generation
of surface meshes were also performed with Amira.
Volume, in cubic millimeters, or mean volumes, ac-
companied by standard error of the mean (SEM) if
multiple equivalent imaging sessions were analyzed,
are presented. In the reproducibility study, the coeffi-
cient(s) of variation (CV) was calculated as the appro-
priate standard deviation divided by the mean, and
expressed as a percentage. For all other studies, a sin-
gle determination is presented.
Cell culture
For orthotopic prostate tumor implantation in nude mice,
CWR22Rv1 cells [25] were acquired from American Type
Culture Collection (Manassas, VA) and grown in Roswell
Park Memorial Institute 1640 (RPMI) medium containing
glutamine and antibiotics with 10 % fetal calf serum. Prior
to injection, cells were washed with phosphate buffered
saline, harvested with trypsin/Ethylenediaminetetraacetic
acid solution, and pelleted. Cells were re-suspended in
RPMI media and an equal volume of Matrigel (Corning,
Bedford, MA) was added.
Image-guided orthotopic prostate tumor establishment
Nude mice were imaged using high-frequency ultra-
sound, as above, prior to tumor xenografting to establish
baseline images. For implantation, image acquisition
was performed with the 704b probe using enhanced
abdominal visualization in 3D-mode. Physiological sta-
tus (electrocardiogram, respiration, blood pressure,
and body temperature) of the mice was monitored
during each image-guided injection. While monitoring
these images, a 30-gauge needle on a syringe was posi-
tioned with a micro-manipulator into the junction of the
two lobes of the anterior prostate. A volume of 10 μL con-
taining 1x106 tumor cells in 50 % Matrigel was injected
over 20 s. The syringe was then withdrawn, ultrasound gel
removed, and mice allowed to recover. Mice were imaged
weekly for eight weeks to monitor development of the
orthotopic prostate tumor xenografts.
Statistical analysis
Prostate volume was normalized to pre-castration vol-
ume for each animal and the mean of group of each
time (+/− SEM), relative to pre-castration volume is pre-
sented in each data set. Comparison between groups was
analyzed by one-way ANOVA with Dunnetts’s post-hoc
test. Subsets of the data were quantitated independently
by two blinded observers to create a Bland-Altman plot
[26, 27]. The means of the prostate volumes, generated by
two independent observers, were plotted on the horizontal
axis, and the differences between the two observers were
plotted on the vertical axis. Differences were considered
statistically significant for a value of P < 0.05.
Singh et al. BMC Urology  (2015) 15:97 Page 3 of 11
Results
Ultrasound imaging of WT mouse prostate
Prostates of four normal mature mice were imaged using
high frequency ultrasound to assess organ volume. Im-
ages of three orthogonal (transverse, coronal and sagittal)
planes of the ventral prostate (VP) were acquired and inte-
grated 3D images produced using VisualSonics software.
The rodent prostate gland is composed of multiple lobes:
ventral, dorsal, lateral and anterior, which are interdigi-
tated into surrounding tissues [28], while in humans the
gland is non-lobular (unitary). The mouse VP has a larger
epithelial component and therefore a larger volume of lu-
minal prostatic secretions relative to the dorsal-lateral
prostate (DLP) lobes, which share ducts and have similar
proportions of epithelial and stromal components, and
therefore are often considered together. As the VP is most
echogenically distinct, segmentation of this lobe is most
accurate, and henceforth reported when describing nor-
mal prostate volume changes. Image sets for two of these
mice, M1 and M2, are illustrated in Fig. 1a. 3D images
were imported into Amira visualization software, manually
outlining the bladder (yellow) and VP (green) in all three
Fig. 1 Ultrasound volume quantitation of mouse ventral prostate is highly reproducible. a Upper sets of panels (for mice M-1 and M-2) depict the
ultrasound images of the lower genitourinary system resolved into three orthogonal planes (transverse, coronal and sagittal, as indicated) and the
corresponding integrated 3D images. The lower set of panels (for mice M-1 and M-2) illustrates the process of segmentation of the relevant anatomic
structures (bladder in yellow, ventral prostate in green) using the Amira software. b Amira generated segmented ultrasound image of the lower
genitourinary system from mouse M-1, including bladder (yellow), seminal vesicle (blue), testes (purple), ventral prostate (green) and vas
deferens (red). c The ventral prostate volume for each of four mice was repeatedly determined. Each symbol represents an independent
determination for a given mouse. Columns denote the mean and error bars the SEM. M-1, M-2 and M-3 were imaged four times, while
M-4 was imaged twice.
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planes (Fig. 1a, lower set of panels for each mouse). Using
the segmentation illustrated in Fig. 1a, Amira was
employed to produce 3D reconstructions of these or-
gans, as well as the seminal vesicles and vas deferens
(Fig. 1b). To assess the reproducibility of this method
for determining the volume of the VP, the same four
mice were each imaged four times. Based on the corre-
sponding segmentation and 3D reconstruction, the vol-
umes of the ventral lobes of these mouse prostates were
computed using Amira (Fig. 1c). The average VP volume
for these mice was 19.03 +/− 3.01 mm3; (mean +/− SEM,
n = 4). The intra-mouse variability was quite low (CV%=
5.0 %), suggesting that for a mature mouse a single im-
aging session is sufficient to determine the baseline
prostate volume for further studies that measure organ
volume regulation.
Regression of WT prostate volume after castration
Advanced, recurrent, and metastatic prostate cancer is
typically controlled using androgen deprivation therapy
(ADT) [29]. ADT induces apoptosis of the epithelial cells,
resulting in regression of normal and diseased prostate
glands as well as disseminated tumor in both patients and
the corresponding mouse models [3, 28, 30]. During cas-
tration, the VP undergoes greater regression than other
lobes due to the relatively higher proportion of epithelial
cells [19, 31, 32]. To determine the ability of high fre-
quency 3D ultrasound to monitor prostate regression,
four WT mice were surgically castrated and VP vol-
ume assessed every 3 or 4 days thereafter by ultra-
sound imaging. We observed significant reduction of
VP volume in all mice from day 4 through day 14
(Fig. 2a). Amira derived volumes indicate that by day
4, the ventral prostate lobes regressed 39 ± 3 %. This
progressed to 68 ± 3 % on day 7 and was further re-
duced to 84 ± 2 and 92 ± 2 % on day 10 and 14, re-
spectively, relative to the corresponding mouse’s
intact VP volume (P < 0.001, Fig. 2b). The normalized
CVs (relative to the intact VP volume for each
mouse, “intra-mouse CV”) were 6.8 %, 5.3 %, 2.2 %,
3.8 % for days 4, 7, 10, and 14, respectively, much
smaller than the overall VP volume variance of
12.6 % (“inter-mouse CV”) when not normalized to
pre-castration volume, as would be the case if one
were to examine VP volumes for groups of mice
sacrificed serially.
Regrowth of ventral prostate volume in normal mice
The prostate of castrated mice returns to its pre-
castrated size following 2 to 3 weeks of androgen sup-
plementation [19, 31]. Two weeks following castration,
the four mice depicted in Fig. 2 were supplemented daily
with DHT and changes in prostate volume were moni-
tored using high frequency 3D ultrasound imaging.
Following manual segmentation and 3D reconstruction
using Amira software to delineate the bladder (yellow
pseudocolored structure in Fig. 3a) and ventral prostate
(green structure in Fig. 3a), we calculated the volume of
the VP for these mice. There was a steady increase in
the ventral prostate volume, from 8 % of the pre-
castrated volume at the beginning of DHT treatment, to
36.4 ± 5, 49.57 ± 4, 59 ± 5, and 70 ± 0.5 % on days 2, 4, 6,
and 8, respectively. This represents regeneration of two-
thirds of the VP volume in eight days (Fig. 3b). The vari-
ability of this regeneration appears to be higher at inter-
mediate time points (21.7 % CV at day 2, 16.7 % CV at
day 4, 13.6 % CV at day 6) compared to the final meas-
urement (2.4 % CV at day 8), suggesting that this repre-
sents underlying biological variability in the rate of
regrowth, rather than reflecting inherent variability in
our imaging technique.
Fig. 2 Castration induced prostate regression monitored by high-
resolution 3D ultrasound imaging. Imaging of VP volume in four mice,
post-castration. a Amira generated 3D volume reconstructions from
ultrasound images, for four mice (M-1 through M-4). Segmentation of
the bladder (yellow) and the ventral prostate (green) is illustrated. b Plot
of ventral prostate volume regression. VP volume was normalized to
pre-castration (P) volume for each animal and the mean (columns, ±
SEM) of the group at the indicated day, relative to pre-castration
volume. Symbols correspond to M-1 (square); M-2 (circle); M-3
(diamond) and M-4 (triangle).
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Intra- and inter-observer variability
To examine the precision of high frequency ultrasound
measurement of the mouse VP volume, the images gener-
ated in Figs. 2 and 3 were blinded and reanalyzed by the
primary reviewer and a secondary reviewer [20, 33–35].
Following segmentation and 3D reconstruction, the vol-
umes were recorded, sent to an honest broker, decoded,
and the intraclass correlation coefficients and variability
for intra- and inter-observer assessments were calcu-
lated [33]. Intra-observer correlation was quite robust,
with r2 = 0.995 (Fig. 4a). The mean intra-observer devi-
ation of individual measurements, as measured by
Bland-Altman analysis was 0.8 % (Fig. 4b), suggesting
strong confidence in the reproducibility of the high fre-
quency ultrasound 3D reconstruction of the VP vol-
ume. In addition, this data was blinded and quantitated by
two independent observers and inter-observer agreement
analyzed by Bland Altman analysis (Fig. 4c and d). Volume
correlation for the VP was r2 = 0.945 (Fig. 4c), and the
mean deviation 3.0 % (Fig. 4d). The interclass correlation
coefficient for measurements of volume between the first
and second examiner also revealed that the intra- and
inter-observer variability for regression of the ventral
prostate was 2.5 and 6 %, respectively, indicating that dif-
ferences between the groups of mice were not due to ob-
server bias.
Ultrasound imaging of hyperplastic mouse prostate
The volume of the ventral prostate was monitored
during development in a mouse model of benign pros-
tatic hyperplasia using high frequency ultrasound im-
aging. Pb-PRL transgenic males developed a significant
enlargement of the prostate gland, characterized primar-
ily by hyperplasia of the stromal compartment, distended
ductal structures, and focal areas of glandular dysplasia
[22]. Two Pb-PRL mice were monitored from 16 to
30 weeks of age, and one of these an additional four
weeks. Ventral prostate and bladder were manually
segmented and boundaries in parallel slices and Amira
three-dimensional reconstructions are shown in Fig. 5a.
Ultrasound images of the hyperplastic prostates were ac-
quired using the 710 probe for the wider field of view.
Computed VP volumes of the Pb-PRL transgenic mice
from 16 to 30 weeks (and 34 weeks for mouse B1) are
plotted in Fig. 5b. Fortuitously, an animal care issue unre-
lated to prostate volume required that a single Pb-PRL
mouse (not one of the two monitored in Fig. 5) be sacri-
ficed at 28 weeks of age, and so the wet weight of micro-
dissected ventral prostate was then determined to be
80 mg, while 3D reconstruction of high frequency ultra-
sound of this mouse abdomen, performed on the same
day, resulted in a prostate volume of 82 mm3 (data not
shown). Prolactin-driven prostate volume increases rap-
idly from 20 weeks of age, and slows by 30 weeks of age,
while continuing to grow slowly thereafter (data not
shown). Unfortunately, attempts to microdissect the BPH
prostates at later ages proved unsuccessful due to the in-
terdigitated nature of the diseased prostate into the sur-
rounding tissues.
Development of orthotopic xenografts
We used high frequency ultrasound imaging to guide
the establishment and monitor the growth of an ortho-
topic human prostate cancer mouse xenograft model.
The genitourinary anatomy of nude mice was imaged by
high resolution, high frequency ultrasound (using the
VisualSonics 704 probe) and the junction of the anterior
Fig. 3 Ventral prostate lobe re-growth in previously castrated mice,
following administration of exogenous DHT. a Amira generated 3D
volume reconstructions from ultrasound images, of four mice (M-1
through M-4), acquired 2, 4, 6 and 8 days following the administration
of DHT to the cohort of day 14 castrated mice shown in Fig. 2
(corresponding to the mice in the right-most column of B).
Segmentation of the bladder (yellow) and the ventral prostate
(green) is illustrated. b Plot of ventral prostate volume, following
DHT administration, over time (days). Volumes determined at
each time point were normalized to the pre-castration (intact)
volume (in Fig. 2). Columns denote the mean and error bars
correspond to the SEM. Symbols correspond to M-1 (circle); M-2
(diamond); M-3 (square) and M-4 (triangle).
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prostate lobes was identified. A syringe needle was then
aligned with the junction and advanced into a lobe of
the anterior prostate (circled in Fig. 6a) using the needle
guide overlay feature of the VisualSonics software that al-
lows for the simultaneous visualization of the needle align-
ment and injection target on the monitor. CWR22Rv1
cells in matrigel were injected directly into a lobe of the
anterior prostate and were visualized post-injection as the
hyperechoic signature at the end of the hypoechoic needle
displacement track in Fig. 6a (right side). Non-invasive
high frequency ultrasound imaging was used to identify
the site of origin of the tumor and then to serially monitor
growth of the CWR22Rv1xenografts. We observed tumor
growth starting at week 3 in one lobe of the anterior pros-
tate (volume approximately 10 mm3; Fig. 6b, “W3” and by
the fourth week tumor volume increased rapidly, reaching
the field of view limit of the 704 probe to simultaneously
visualize the entire tumor volume (approximately 60 mm3;
Fig. 6b, “W4”). Tumor growth was further monitored using
the 25 MHz frequency 710b probe from week 5 to week 7
post-implantation (Fig. 6b, bottom) or until tumor volume
reached 750 mm3, when the xenograft hosts were sacri-
ficed. For the six xenografts in this proof of principle, we
observed most xenografts grew at a rate of ~50 mm3 per
week, while one xenograft had a much more aggressive
growth phenotype (doubling every week, Fig. 6c).
Discussion
Androgens regulate prostate growth and neoplastic
phenotype. They promote mitosis and differentiation of
rodents prostate ductal epithelium, and further inhibit
apoptosis of differentiated cells [36]. Androgen with-
drawal, through surgical castration or pharmacological
blockade, induces apoptosis of the ductal secretory epi-
thelium, but not the basal epithelium or stromal cells
[37]. The small size of the mouse prostate (25 mm3) ver-
sus the human prostate (25 cm3) and the difficulty in
reproducibly excising the prostate from surrounding tis-
sues makes it challenging to accurately determine pros-
tate volume by weighing or histological analysis at
Fig. 4 Intra- and inter-observer variability of volume measurement by ultrasound imaging. Intra-observer variation (a, b). a Linear correlation plot
of two independent sets of volume measurements, performed (blinded) by a single observer (data from Figs. 2 and 3 image sets). The correlation
coefficient, r2 = 0.995. b Bland-Altman plot of the data from (a). Dashed lines correspond to the 95 % confidence interval. The mean deviation of
individual measurements was 0.8 % (n = 36). Inter-observer variation (c, d). c Linear correlation plot of two independent sets of volume determina-
tions, performed (blinded) by two separate examiners (data from Figs. 2 and 3 image sets). The correlation coefficient, r2 = 0.945. d Bland-Altman
plot of the data from (c). Dashed lines correspond to the 95 % confidence interval. The mean deviation of individual measurements was
3.0 % (n = 32).
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necropsy [3, 19, 20, 38–40]. Moreover, as noted in the
Introduction, restricting analysis to animals at necropsy
would require large numbers of animals for longitudinal
studies of tumor or BPH response to therapy and is in-
herently less accurate than repeated volumetric imaging
of individual animals over time. Biochemical cancer bio-
markers, such as serum PSA for human prostate xeno-
graft volume [11, 41], and serum PSP94 for mouse
tumor volume [42], correlate well with tumor volume
but are androgen driven, and therefore problematic for
monitoring therapies directed at androgen signaling.
Thus, there is a need for a relatively rapid and inexpen-
sive, yet quantitative, methodology for imaging the mur-
ine prostate.
In 2006, Albanese and colleagues [43] pioneered the use
of high field strength MRI to measure prostate volume in
mouse tumor models. Subsequently, we developed [19]
and utilized [20] a quantitative and reproducible magnetic
resonance-based anatomical imaging approach (MRI-
CHESS) to quantitate murine prostate volume changes in
mouse models. CHESS (chemical shift suppression) allows
suppression of MR signal arising artifactually from sur-
rounding peri-prostatic fat, revealing boundaries of the
prostatic lobes more accurately, and differentiating the
ventral from the dorsal-lateral lobes. However, since MRI
requires costly instrumentation, with high operating costs,
and the additional expense of a dedicated operator [44], it is
not available to the vast majority of prostate cancer investi-
gators. Moreover, achieving the very high spatial resolution
required to accurately determine prostate volumes with
Fig. 5 Quantitative monitoring of a benign prostatic hyperplasia in
probasin-PRL transgenic mice. a Amira generated 3D reconstructions
from ultrasound images, for two probasin-PRL mice (B-1 and B-2), ac-
quired at 30, 34, 38 and 41 weeks of age. Segmentation of the blad-
der (yellow) and the ventral prostate (green) is illustrated. b Plot of
ventral prostate volume over time (age, in weeks). Symbols corres-
pond to the same animal imaged serially.
Fig. 6 Monitoring growth of orthotopically implanted human
prostate cancer xenograft. a Ultrasound image demonstrating 30-
gauge needle injection (needle track is above and to the right green
line) of 106 CWR22Rv1 castration resistant prostate cancer cells into
the murine anterior prostate lobe (yellow outline), before (left) and
after (right) injection of the cells. b Amira generated 3D volume
reconstructions from ultrasound images over time (weeks).
Segmentation of the xenograft tumor in the anterior prostate (red),
the bladder (yellow) and the ventral prostate (green) is illustrated.
Images in upper three panels were acquired with a 704 probe
(80 mm FOV); lower images were acquired with a 710 probed
(120 mm FOV). c Plot of orthotopic tumor volume increase over
time (age, in weeks). Symbols correspond to the same animal
imaged serially.
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MRI necessitates long scan times, and therefore this meth-
odology is decidedly low throughput. Finally, the significant
infrastructure required to support an MRI facility often pre-
cludes location within the clean zone of an animal facility,
which hampers the ability to image immunocompromised
animals (such as xenograft-bearing athymic nude mice)
which require a pathogen-free environment.
Given these obstacles to the implementation ofMRI, and in
the absence of other well-characterized alternative quantita-
tive imaging protocols, optical imaging, employing constitu-
tive luciferase reporters for bioluminescent imaging (BLI), has
become the de facto technology for monitoring the growth
and regression (in response to therapy). However, correlation
of BLI intensity with tumor volume is poor (R2 = 0.6-0.8), par-
ticularly for larger tumors (>200 mm3) [44]. Problems arise
due to inconsistent luciferin penetration of organs generally
[45], and tumor specifically due to vascularity of the hypoxic
tumor necrotic core [46], and this may be further exacerbated
in a trial of pro-apoptotic therapies. Further, BLI intensity can
be reduced by surrounding tissues, such as bladder with vari-
able urine content [16] or incomplete fur removal [44], and
thus volume estimatesmay be unreliable for prostate. Increas-
ing tumor volume also directly reduces the ability of light to
escape [14], and this imaging modality may be more properly
described as qualitative [15].
While micro-computed tomography is lower cost than
MR imaging, it cannot effectively distinguish prostate tumor
from surrounding normal tissue [11]. In contrast, ultrasound
imaging instrumentation is much more amenable to use in
animal core facilities due to both acquisition and operating
costs, as well as instrument size. Volume determinations
using a micro-transrectal transceiver [41], has been shown
to correlate well with volumes determined from the wet
weight of dissected orthotopic prostate tumors, but are tech-
nically challenging. High frequency ultrasound measure-
ments using the VisualSonics Vevo 770, that employs an
external probe, show good correlation (r2 = 0.85) with dis-
sected large autochthonous tumors [11]. Moreover, the rela-
tive ease of operation facilitates reasonable through-put,
since scan times are on the order of 30 min including pre-
parative anesthesia and depiliation. 2D-ultrasound allows in-
plane sizing of tumors with a diameter as small as ~3 mm,
which is within 10 % of the diameter of mouse prostate, as
revealed by histology [35], but single slice imaging is subject
to sampling error, few prostate tumor imaging studies report
volume changes less than 10 mm3, and tumors with non-
uniform shapes are poorly described by 2D-imaging. 3D-
ultrasound for human prostate is a more precise and
accurate methodology for determining prostate volume [47,
48]. High resolution 3D-ultrasound computed volumes from
0.5 to 10 mm3 correlate well with caliper measurements and
histology for endometriotic cysts [45], and colorectal xeno-
grafts [34]. We therefore sought to exploit the precision of
3D-ultrasound by adapting it to accurately quantitate very
small changes (as little as 3 % of a volume as small as
~10 mm3) in the mouse prostate under various physiological
and pathological conditions. Figs. 1, 2 and 3 demonstrate
that our use of the VisualSonics instrumentation and Amira
3D software for reconstruction allows very reproducible
measurements of VP volume in intact mice (Fig. 1), mice
undergoing castration induced regression (Fig. 2) and mice
undergoing DHT supplementation induced re-growth
(Fig. 3). In these imaging sessions theVP volumes varied from
~20mm3 for intact animals to ~5mm3 for regressed animals,
emphasizing the high degree of accuracy in measuring very
small glands. Because image processing involves operator-
dependent segmentation of the raw US images, we per-
formed blinded intra- and inter-operator assessments of
reproducibility (Fig. 4) and found excellent agreement
(CV ~3 %). We should note that assessment does not re-
quire extensive training in mouse anatomy, as individuals
who had no prior experience were able to readily master the
segmentation protocol within weeks. We also applied our
methodology to two pathological animals models: prolactin
transgene-driven benign prostatic hyperplasia (Fig. 5) and
orthotopic implantation of human prostate cancer xeno-
grafts (Fig. 6). In both cases, we were able to detect patho-
logical changes which increased the volumes by as little as
10 % (c.f. Fig. 6b, W3). In addition, the small size of the nor-
mal anterior prostate host site for implantation leads to vari-
ability when injecting tumor cells to establish prostate
orthotopic xenografts, impairing reproducibility in the either
the microenvironment or mis-location of the implantation
and concomitant dissemination of the tumor in the periton-
eum [49]. Thus, in contrast to other imaging modalities,
which require large volume changes to be appreciated, this
methodology reveals themagnitude ofmorphological changes
more typically seen in human pathology, where the volumetric
alterations are a small fraction of the original organ volume. Fi-
nally, in data not shown here, we have use the same protocol
to image tumor formation in PTENdeficientmousemodels of
human prostate cancer and can similarly detect presumptive
tumorwhich represents less than 10% of prostate volume.
Conclusions
We have developed an accurate, precise, and reprodu-
cible high frequency ultrasound imaging and 3D
reconstruction protocol to serially quantitate prostate
volume in live mice. This protocol allows determination
of normal prostate growth and regression following
hormone manipulation (ADT), as well as growth fol-
lowing androgen supplementation, in a model of BPH
and in orthotopic prostatic tumor xenograft models.
We anticipate that the utility of this technique can be
extended to determining the efficacy of novel therapeu-
tics in pre-clinical trials in mouse models of prostate
cancer and benign prostatic hyperplasia.
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